Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a variety of off-the-shelf anti-CA9 products and customized services to meet the specific needs of researchers. Throughout the process of CAR-T therapy development, our team provides comprehensive technical support and consultation to ensure the success of your research.
Carbonic anhydrase 9 (CA9/CAIX) is an enzyme that in humans is encoded by the CA9 gene. CAIX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma(ccRCC), but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. CAIX is also the most widely expressed gene in response to hypoxia. Its crucial role in intracellular pH maintenance represents the means by which cancer cells adapt to the toxic conditions of the extracellular milieu. Furthermore, the activity of CA IX stimulates the migratory pathways of cancer cells and is connected with the increase of the aggressive/invasive phenotype of tumors. CA IX expression in many types of tumors indicates its relevance as a general marker of tumor hypoxia. Moreover, its expression is closely related to the prognosis of the clinical outcome in several tumor types. All above-mentioned facts support the strong position of CA IX as a potential drug therapy target.
Clear cell renal cell carcinoma (ccRCC)
Anti-CA9 CAR-T Expression Test
Creative Biolabs provides state-of-the-art anti-CA9 CAR-T expression tests. We provide CA9 protein products for the evaluation of the anti-CA9 CAR expression on the surface of T cells. Our experts perform flow cytometry, western blotting, and QPCR tests to provide sensitive and specific measurements of CAR mRNA and protein levels.
Fig.1 Western blot analysis and flow cytometry analysis of the expression of anti-CA9 CAR.1
Anti-CA9 CAR-T Proliferation Test
The Anti-CA9 CAR-T proliferation test is an essential tool for evaluating the potential of CAR-T cells to proliferate and expand in response to specific stimuli. At Creative Biolabs, we offer comprehensive CAR proliferation assay services to ensure that our CAR-modified immune cells possess the desired proliferative capacity.
Fig.2 The proliferation curves of sunitinib-treated anti-CA9 CAR-T cells by cell counting.2
Anti-CA9 CAR-T Cytokine Release Test
Our laboratory offers a comprehensive range of cytokine release assays to determine the release of various cytokines, including TNF-α, IFN-γ, IL-2, IL-6, and IL-8. These assays enable researchers to monitor the safety and efficacy of CAR-T cell therapy in preclinical and clinical trials.
Fig.3 The release of various cytokines.1
Anti-CA9 CAR-T In Vitro Cytotoxicity Assay
We provide cytotoxicity assay services for measuring the rate of target cell death induced by the CA9 CAR-T cells. The test provides valuable information about the cytotoxic potential and specificity of the CA9 CAR-T cells.
Fig.4 In vitro cytotoxicity of anti-CA9 CAR-T against CAIX-transfected U251 cells as measured by LDH release assay.2
Efficacy Test of Anti-CA9 CAR-T
Creative Biolabs offers anti-tumor efficacy test services for CA9 CAR-T cells in animal models. Our team ensures that our clients receive accurate and reliable results, allowing them to make informed decisions regarding their CAR-T therapy research.
Fig.5 The therapeutic potential of the anti-CA9 CAR-T cells was assessed in the glioblastoma xenograft mouse model. The anti-CA9 CAR-T cells significantly suppressed tumor growth.2
Toxicity Evaluation Anti-CA9 CAR-T
Our CAR-T toxicity study services provide a comprehensive approach to evaluating the safety and potential side effects of anti-CA9 CAR--T cell therapy. Our services include cytokine release analysis, on/off-target toxicologic analysis, and tumorigenicity analysis.
Fig.6 Cytokine secretion in the supernatant of tumor and blood. The cytokines (IFN-γ, TNF-α, and IL-2) were analyzed by ELISA.2
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-T-1-M305-2 | Anti-CAIX scFv h(CD28) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD28 | Lentiviral | T cell | ||
| CAR-T-1-M305-G | Anti-CAIX scFv h(FcεRIγ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-1-M305-Z | Anti-CAIX scFv h(CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M305-2G | Anti-CAIX scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-2-M305-2Z | Anti-CAIX scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M305-4G | Anti-CAIX scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-2-M305-4Z | Anti-CAIX scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M305-8Z | Anti-CAIX scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD8-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M305-BZ | Anti-CAIX scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-M305-CZ | Anti-CAIX scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-b2c-CD3ζ | Lentiviral | T cell | ||
| CAR-T-3-M305-2BZ | Anti-CAIX scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-3-M305-2XZ | Anti-CAIX scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | G250 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L404-BZ | G250 h(41BB-CD3ζ) CAR, [T] | Human | Humanized | scFv-41BB-CD3ζ | Lentiviral | T cell | |||
| CAR-T-2-L404-CZ | G250 h(b2c-CD3ζ) CAR, [T] | Human | Humanized | scFv-b2c-CD3ζ | Lentiviral | T cell | |||
| CAR-T-3-L404-2BZ | G250 h(CD28-41BB-CD3ζ) CAR, [T] | Human | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |||
| CAR-T-2-L404-2Z | G250 h(CD28-CD3ζ) CAR, [T] | Human | Humanized | scFv-CD28-CD3ζ | Lentiviral | T cell | |||
| CAR-T-2-L404-2G | G250 h(CD28-FcεRIγ) CAR, [T] | Human | Humanized | scFv-CD28-FcεRIγ | Lentiviral | T cell | |||
| CAR-T-3-L404-2XZ | G250 h(CD28-OX40-CD3ζ) CAR, [T] | Human | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |||
| CAR-T-1-L404-Z | G250 h(CD3ζ) CAR, [T] | Human | Humanized | scFv-CD3ζ | Lentiviral | T cell | |||
| CAR-T-2-L404-4Z | G250 h(CD4-CD3ζ) CAR, [T] | Human | Humanized | scFv-CD4-CD3ζ | Lentiviral | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
